FGFR2 and cholangiocarcinoma: According to the FIGHT-202 study, the objective response rate (ORR) of patients with advanced CCA harboring FGFR2 fusions/rearrangements treated with pemigatinib was 35.5%, with three patients achieving complete response (CR) and a disease control rate (DCR) of 82%.